% study characteristics

{% caption group
\newgeometry{left=2.5cm, right=2.6cm, top=2cm, bottom=2cm}
% \captionsetup{width=1\textheight, font=footnotesize, skip=7pt}


% \\ \textsuperscript{4}
% \\ \textsuperscript{5}

\begin{landscape}
  \footnotesize
  \begin{ThreePartTable}
    \begin{TableNotes}
      \item[1] Significant predictors in Lucero et al. are in fact adjusted for sex and age. Kajaia et al present the overall p-value across all predictor categories and 95\% CIs for each category. Overall p-values are presented, and the trend commented on.
      \item[2] 3 studies adjusted the multivariable model for other non-significant variables, including Lucero et al. (sex, admission and discharge haemoglobin, admission spleen size), Mondal et al. (sex, age, treatment, and various others), Gorski et al. (age, sex, calendar year, treatment centre)
      \item[3] Shorter symptom duration associated with higher relapse risk in Burza 2014.
      \item[4] 166 relapses cases could be matched with primary case records, and does not reflect total relapse number.
      \item[5] Spleen size recorded as Hackett grade in Gorski 2010.
      \item[*] 0.05 $\leq$ p < 0.1.
      \item[**] 0.01 $\leq$ p <0.05; 
      \item[***] 0.001 $\leq$ p <0.01 
      \item[****] p < 0.001.
      \item[$\dagger$] p <0.05 (inferred as confidence interval does not cover null).
      \item[$\dagger\dagger$] Significance level not stated.
    \end{TableNotes}
    \begin{longtable}[c]{@{} L{3.1cm} L{2.5cm} L{2cm} L{1.7cm} L{6cm} L{6cm} @{}}

      \caption{Summary of studies predictors of VL relapse in immunocompetent patients. Excluding: studies only looking at treatment regimen or biomarkers. BPKIHS: B.P. Koirala Institute of Health Sciences; ISC: Indian subcontinent; KAMRC: Kala-azar Medical Research Centre; MA: meglumine antimoniate; MSF: Médecins Sans Frontières; Hb: haemoglobin; LAMB: liposomal amphotericin B; MF: miltefosine; PM: paromomycin; RBC: red blood cell; SDA: single dose liposomal amphotericin B 10mg/kg; SSG: sodium stibogluconate; VL: visceral leishmaniasis; wks: weeks; yrs: years.}\label{tab:relapse-rf} \\
      \toprule
      Study                                        & Location                                                          & Treatment                 & n (relapse) \%       & Significant predictors \textemdash\ unadjusted model\tnote{1}                                                                                                                                                                                                                    & Significant predictors -- adjusted model\tnote{2}                                                                                                                                                                                                                                                                                                                    \\
      \midrule
      \endfirsthead

      \caption[]{continued}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               \\
      \toprule
      Study                                        & Location                                                          & Treatment                 & n (relapse) \%       & Significant predictors \textemdash\ unadjusted model\tnote{1}                                                                                                                                                                                                                    & Significant predictors -- adjusted model\tnote{2}                                                                                                                                                                                                                                                                                                                    \\
      \midrule
      \endhead

      % \midrule
      \multicolumn{6}{r}{\textit{continued on next page}}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 \\
      \endfoot

      \bottomrule
      \insertTableNotes
      \endlastfoot

      \textbf{ISC}                                 &                                                                   &                           &                      &                                                                                                                                                                                                                                                                        &                                                                                                                                                                                                                                                                                                                                                                      \\
      \hspace{0.5em}Burza 2014\cite{burza2014}     & MSF clinics, Bihar, India                                         & 20mg/kg LAMB (4 x 5mg/kg) & 8,537~(119) 13.9\%   & age <5\mtnote{****}, age $\geq$ 45\mtnote{**} vs. 15--30~yrs; male sex\mtnote{***}; other backwards caste\mtnote{*} vs.\ general category; symptom duration\tnote{3} > 8 wks\mtnote{***}, > 4 to $\leq$8wks\mtnote{**} vs. $\leq$4 wks; spleen size change $\leq$0.5cm/day vs. >0.5cm/day                                      & age~<5\mtnote{****}, age~$\geq$45\mtnote{**} vs. 15--30 yrs; male sex\mtnote{***}; symptom duration\tnote{3} >8~wks\mtnote{**}, >4 to~$\leq$8wks\mtnote{**} vs. $\leq$4 wks; spleen size change $\leq$0.5cm/day vs.~>0.5cm/day                                                                                                                                                                                    \\
      \hspace{0.5em}Goyal 2019\cite{goyal2019}     & Public health facilities, Bihar, India                            & SDA; LAMB+MF; MF+PM       & 1,353 (75) 5.5\%     & age 2--12~yrs\mtnote{**} vs. >12~yrs; symptom duration $\leq$8~wks\mtnote{***} vs. >8 wks; treatment\mtnote{****}                                                                                                                                                                                 & age 2--12~yrs\mtnote{$\dagger$} vs. >12~yrs; symptom duration $\leq$8~wks\mtnote{$\dagger$} vs. >8 wks; treatment MF+PM\mtnote{$\dagger$} vs. SDA                                                                                                                                                                                                                                      \\
      \hspace{0.5em}Goyal 2020\cite{goyal2020}     & [as above]                                                        & [as above]                & 1,750 (79) 4.5\%     & age 2--12~yrs\mtnote{$\dagger\dagger$} vs. >12~yrs; treatment with MF+PM\mtnote{$\dagger\dagger$}                                                                                                                                                                                  & age 2--12~yrs\mtnote{***} vs >12~yrs; symptom duration $\leq$8~wks\mtnote{***} vs. >8 wks; treatment MF+PM\mtnote{****} vs. SDA                                                                                                                                                                                                                                                                 \\
      \hspace{0.5em}Lucero 2015\cite{lucero2015}   & MSF clinic, Fulbaria, Bangladesh                                  & 15mg/kg LAMB (3 x 4mg/kg) & 1,521 (39) 2.6\%     & age <5~yrs\mtnote{***}, age~$\geq$40 yrs\mtnote{**} vs. 18--39~yrs; lower admission Hb\mtnote{***}; lower discharge Hb\mtnote{***}; larger discharge spleen size\mtnote{***}                                                                                                                                        & age <5~yrs\mtnote{***}, age~$\geq$40 yrs\mtnote{**} vs. 18--39~yrs; larger discharge spleen size\mtnote{**}                                                                                                                                                                                                                                                                                     \\
      \hspace{0.5em}Mondal 2019\cite{mondal2019}   & Hospital in Mymensingh, Bangladesh.                               & 8 different regimens      & 984 (69) 7.0\%.      & treatments compared only: MD-LAMB*, MF\mtnote{**}, LAMB+PM\mtnote{**}, LAMB+MF\mtnote{***}, SDA\mtnote{****}, PM\mtnote{****}, MF+PM\mtnote{****} vs. SSG                                                                                                                                                                    & treatment: MD-LAMB\mtnote{*}, MF\mtnote{**}, LAMB+PM\mtnote{**}, SDA\mtnote{***}, LAMB+MF\mtnote{****}, PM\mtnote{****}, MF+PM\mtnote{****} vs. SSG                                                                                                                                                                                                                                                                                 \\
      \hspace{0.5em}Rijal 2013\cite{rijal2013}     & BPKIHS, Eastern Nepal                                             & MF                        & 115 (24) 20.9\%      & age $\leq$12 yrs\mtnote{**} vs.\ >12 yrs                                                                                                                                                                                                                                         & [not performed]                                                                                                                                                                                                                                                                                                                                                      \\
      \hspace{0.5em}Sundar 2019\cite{sundar2019}   & KAMRC, Bihar, India                                               & SDA                       & 1,143 (66) 5.8\%     & age $\leq$15 yrs\mtnote{*} vs.\ >15 yrs; male sex\mtnote{**}; weight $\leq$ 30kg\mtnote{**} vs. >30kg; spleen size >4cm\mtnote{***} vs. $\leq$4cm                                                                                                                                                            & male sex\mtnote{***}; weight $\leq$ 30kg\mtnote{**} vs. >30kg; spleen size >4cm\mtnote{***} vs. $\leq$4cm                                                                                                                                                                                                                                                                                        \\
      \midrule
      \textbf{East Africa}                         &                                                                   &                           &                      &                                                                                                                                                                                                                                                                        &                                                                                                                                                                                                                                                                                                                                                                      \\*
      \hspace{0.5em}Gorski 2010\cite{gorski2010}   & MSF clinics, South Sudan                                          & SSG, SSG/PM, LAMB         & 8,090 (166)\tnote{4} & treatment centre: Lankien\mtnote{****} vs other; admission spleen size\tnote{5} \mtnote{***}; discharge spleen size\mtnote{***}; treatment\mtnote{****}; lower \% gain in body weight\mtnote{*}                                                                                                                     & admission spleen size\tnote{5}~1\mtnote{$\dagger$}, 2\mtnote{$\dagger$}, $\geq$3\mtnote{$\dagger$} vs 0; discharge spleen size 2\mtnote{$\dagger$}, $\geq$3\mtnote{$\dagger$} vs 0; treatment SSG/PM\mtnote{$\dagger$} vs SSG                                                                                                                                                                            \\
      \hspace{0.5em}Kennedy 2024\cite{kennedy2024} & Chemolingot Sub-county Hospital, Baringo County, Kenya            & SSG/PM, LAMB              & 248 (17) 6.9\%       & anaemia\mtnote{*}; shorter hospital stay\mtnote{*}                                                                                                                                                                                                                                       & [not performed]                                                                                                                                                                                                                                                                                                                                                      \\
      \textbf{Europe}                              &                                                                   &                           &                      &                                                                                                                                                                                                                                                                        &                                                                                                                                                                                                                                                                                                                                                                      \\
      \hspace{0.5em}Kajaia 2011\cite{kajaia2011}   & Institute of Parasitology and Tropical Medicine, Tbilisi, Georgia & MA                        & 300 (21) 7.0\%       & age\mtnote{**}: higher risk in <1 yrs; symptom duration\mtnote{***}: higher risk with longer duration; Hb\mtnote{****}: higher risk with Hb <60g/l; RBC\mtnote{*}: higher risk <2.0$\times10^{12}/l$; lymphocytes\mtnote{**}: higher risk with $\geq$80\%; admission spleen size\mtnote{**}: higher risk with larger spleens & age <1 yr\mtnote{**} vs. >1 yr; symptom duration $\geq$90 days\mtnote{***} vs <90 days; Hb <60g/l\mtnote{****} vs. Hb <60g/l                                                                                                                                                                                                                                                                    \\
    \end{longtable}
  \end{ThreePartTable}
\end{landscape}
} % end caption group
\restoregeometry